| Style | Citing Format |
|---|---|
| MLA | Ganjalikhanihakemi M, Xu L, Bazhin AV. "Editorial: Cellular and Molecular Mechanisms of Immune Checkpoint Blockers in Anti-Leukemia/Lymphoma Immune Therapy." Frontiers in Oncology, vol. 12, no. , 2022, pp. -. |
| APA | Ganjalikhanihakemi M, Xu L, Bazhin AV (2022). Editorial: Cellular and Molecular Mechanisms of Immune Checkpoint Blockers in Anti-Leukemia/Lymphoma Immune Therapy. Frontiers in Oncology, 12(), -. |
| Chicago | Ganjalikhanihakemi M, Xu L, Bazhin AV. "Editorial: Cellular and Molecular Mechanisms of Immune Checkpoint Blockers in Anti-Leukemia/Lymphoma Immune Therapy." Frontiers in Oncology 12, no. (2022): -. |
| Harvard | Ganjalikhanihakemi M, Xu L, Bazhin AV (2022) 'Editorial: Cellular and Molecular Mechanisms of Immune Checkpoint Blockers in Anti-Leukemia/Lymphoma Immune Therapy', Frontiers in Oncology, 12(), pp. -. |
| Vancouver | Ganjalikhanihakemi M, Xu L, Bazhin AV. Editorial: Cellular and Molecular Mechanisms of Immune Checkpoint Blockers in Anti-Leukemia/Lymphoma Immune Therapy. Frontiers in Oncology. 2022;12():-. |
| BibTex | @article{ author = {Ganjalikhanihakemi M and Xu L and Bazhin AV}, title = {Editorial: Cellular and Molecular Mechanisms of Immune Checkpoint Blockers in Anti-Leukemia/Lymphoma Immune Therapy}, journal = {Frontiers in Oncology}, volume = {12}, number = {}, pages = {-}, year = {2022} } |
| RIS | TY - JOUR AU - Ganjalikhanihakemi M AU - Xu L AU - Bazhin AV TI - Editorial: Cellular and Molecular Mechanisms of Immune Checkpoint Blockers in Anti-Leukemia/Lymphoma Immune Therapy JO - Frontiers in Oncology VL - 12 IS - SP - EP - PY - 2022 ER - |